Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

MicroRNA expression profiling in prostate cancer.

Kati P Porkka1, Minja J Pfeiffer, Kati K Waltering

  • 1Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland.

Cancer Research
|July 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification of protein-coding genes associated with metastatic prostate cancer.

Endocrine-related cancer·2025
Same author

Single cell and spatial transcriptomics highlight the interaction of club-like cells with immunosuppressive myeloid cells in prostate cancer.

Nature communications·2024
Same author

Long noncoding RNA EPCART regulates translation through PI3K/AKT/mTOR pathway and PDCD4 in prostate cancer.

Cancer gene therapy·2024
Same author

Germline-specific RNA helicase DDX4 forms cytoplasmic granules in cancer cells and promotes tumor growth.

Cell reports·2024
Same author

Cancer origin tracing and timing in two high-risk prostate cancers using multisample whole genome analysis: prospects for personalized medicine.

Genome medicine·2023
Same author

Identification of long noncoding RNAs with aberrant expression in prostate cancer metastases.

Endocrine-related cancer·2023
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Researchers identified a specific microRNA (miRNA) signature for prostate cancer. These small RNAs show altered expression in tumors, potentially serving as diagnostic and prognostic tools for cancer development and progression.

Area of Science:

  • Molecular Biology
  • Oncology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression.
  • Aberrant miRNA expression is linked to various cancers, including prostate cancer.
  • Identifying cancer-specific miRNA signatures is crucial for diagnostics and therapeutics.

Purpose of the Study:

  • To identify a miRNA signature specific to prostate cancer.
  • To investigate the relationship between miRNA expression and genetic aberrations.
  • To evaluate the potential of miRNAs as diagnostic and prognostic markers for prostate cancer.

Main Methods:

  • miRNA expression profiling using oligonucleotide array hybridization.
  • Analysis of prostate cancer cell lines, xenografts, benign prostatic hyperplasia (BPH), and carcinoma samples.

Related Experiment Videos

  • Array comparative genomic hybridization (aCGH) for genetic aberration analysis.

    • Main Results:

    • Differential expression of 51 individual miRNAs between benign and carcinoma prostate tissues was detected (37 downregulated, 14 upregulated).
    • A significant trend was observed between miRNA expression and miRNA locus copy number, suggesting genetic aberrations target miRNAs.
    • Hierarchical clustering based on miRNA expression accurately separated carcinomas from BPH and classified tumors by androgen dependence.

    Conclusions:

    • A distinct miRNA signature specific to prostate cancer was identified.
    • Genetic aberrations may influence miRNA expression in prostate cancer.
    • miRNAs hold potential as novel diagnostic and prognostic tools for prostate cancer, including predicting treatment response.